TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway

Molecular Metabolism

Volumn 5, Issue 10, 2016, Pages 903-917

  Ghoshal, Sarbani ^a   Zhu, Qingzhang ^a   Asteian, Alice ^a   Lin, Hua ^a   Xu, Haifei ^a   Ernst, Glen ^b   Barrow, James C ^b   Xu, Baoji ^a   Cameron, Michael D ^a   Kamenecka, Theodore M ^a   Chakraborty, Anutosh ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b LIEBER INSTITUTE FOR BRAIN DEVELOPMENT   (United States)

Author keywords

Akt; Diabetes; Energy expenditure; Inositol pyrophosphate; IP6K; Obesity

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLUCOSE; INOSITOL HEXAKISPHOSPHATE KINASE 1; INOSITOL PYROPHOSPHATE; N6 (4 NITROBENZYL) N2 [3 (TRIFLUOROMETHYL)BENZYL] 9H PURINE 2,6 DIAMINE; PHOSPHORIC ACID DERIVATIVE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTI OBESITY EFFECT; ANTIDIABETIC ACTIVITY; ARTICLE; BODY COMPOSITION; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENERGY EXPENDITURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HISTOPATHOLOGY; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; KNOCKOUT MOUSE; LIPID DIET; LIVER MICROSOME; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASMA PROTEIN BINDING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THERMOGENESIS; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; WILD TYPE MOUSE;

EID: 84992170437     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.08.008     Document Type: Article

References (96)

1. [1] Kahn, B.B., Kahn, F.J., Obesity and insulin resistance. Journal of Clinical Investigation 106 (2000), 473–481.
2. [2] Hardy, O.T., C.M., Corvera, S., What causes the insulin resistance underlying obesity?. Current Opinion in Endocrinology Diabetes and Obesity 19 (2012), 81–87.
3. [3] Hainer, V., H.I., Do we need anti-obesity drugs?. Diabetes/Metabolism Research and Reviews 28 (2012), 8–20.
4. [4] Kim, G.W., L.J., Blomain, E.S., Waldman, S.A., Antiobesity pharmacotherapy: new drugs and emerging targets. Clinical Pharmacology & Therapeutics 95 (2014), 53–66.
5. [5] Rodgers, R.J., T.M., Wilding, J.P., Anti-obesity drugs: past, present and future. Disease Models & Mechanisms 5 (2012), 621–626.
6. [6] Vervoort, G., T.C., Do we need new drugs for the treatment of type 2 diabetes mellitus?. Netherlands Journal of Medicine 65 (2007), 157–159.
7. [7] Yanovski, S.Z., Y.J., Long-term drug treatment for obesity: a systematic and clinical review. JAMA 311 (2014), 74–86.
8. [8] Witkamp, R.F., Current and future drug targets in weight management. Pharmaceutical Research 28 (2011), 1792–1818.
9. [9] Holes-Lewis, K.A., M.R., O'Neil, P.M., Pharmacotherapy of obesity: clinical treatments and considerations. American Journal of the Medical Sciences 345 (2013), 284–288.
10. [10] Whittle, A., R.-P.J., Vidal-Puig, A., Pharmacological strategies for targeting BAT thermogenesis. Trends in Pharmacological Sciences 34 (2013), 347–355.
11. [11] Rondinone, C., Serine kinases as new drug targets for the treatment of type 2 diabetes. Current medicinal chemistry-immunology. Endocrine & Metabolic Agents 5 (2005), 529–536.
12. [12] Tseng, Y.H., C.A., Kahn, C.R., Cellular bioenergetics as a target for obesity therapy. Nature Reviews Drug Discovery 9 (2010), 465–482.
13. [13] Choi, J.H., B.A., Estall, J.L., Kajimura, S., Boström, P., Laznik, D., et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466 (2010), 451–456.
14. [14] Hansen, J.B., A.P., Bodvarsdottir, T.B., Wahl, P., Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Current Medicinal Chemistry 11 (2004), 1595–1615.
15. [15] Nilsson, C., R.K., Yan, F.F., Larsen, M.O., Tang-Christensen, M., Laboratory animals as surrogate models of human obesity. Acta Pharmacologica Sinica 33 (2012), 173–181.
16. [16] Collins, S., M.T., Surwit, R.S., Robidoux, J., Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiology & Behavior 81 (2004), 243–248.
17. [17] Buettner, R., S.J., Bollheimer, L.C., High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 15 (2007), 798–808.
18. [18] Cohen, P., A.D., Kinase drug discovery–what's next in the field?. ACS Chemical Biology 8 (2013), 96–104.
19. [19] Chakraborty, A., K.S., Snyder, S.H., Inositol pyrophosphates as mammalian cell signals. Science Signalling, 4, 2011, re1.
20. [20] Wilson, M.S., L.T., Saiardi, A., Inositol pyrophosphates: between signalling and metabolism. Biochemical Journal 452 (2013), 369–379.
21. [21] Thota, S.G., B.R., The emerging roles of inositol pyrophosphates in eukaryotic cell physiology. Journal of Biosciences 40 (2015), 593–605.
22. [22] Shears, S., Towards pharmacological intervention in inositol pyrophosphate signalling. Biochemical Society Transactions 44 (2016), 191–196.
23. [23] Barker, C.J., I.C., Gaboardi, G.C., Berggren, P.O., Inositol pyrophosphates: structure, enzymology and function. Cellular and Molecular Life Sciences 66 (2009), 3851–3871.
24. [24] Saiardi, A., E.-B.H., Snowman, A.M., Tempst, P., Snyder, S.H., Synthesis of diphosphoinositol pentakisphosphate by a newly identified family of higher inositol polyphosphate kinases. Current Biology 9 (1999), 1323–1326.
25. [25] Saiardi, A., N.E., Luo, H.R., Snowman, A.M., Snyder, S.H., Identification and characterization of a novel inositol hexakisphosphate kinase. Journal of Biological Chemistry 276 (2001), 39179–39185.
26. [26] Wundenberg, T., G.N., Lin, H., Mayr, G.W., Discovery of InsP6-kinases as InsP6-dephosphorylating enzymes provides a new mechanism of cytosolic InsP6 degradation driven by the cellular ATP/ADP ratio. Biochemical Journal 462 (2014), 173–184.
27. [27] Chanduri, M., R.A., Malla, A.B., Wu, M., Fiedler, D., Mallik, R., et al. Inositol hexakisphosphate kinase 1 (IP6K1) activity is required for cytoplasmic dynein-driven transport. Biochemical Journal, 2016 p. pii: BCJ20160610.
28. [28] Ghosh, S., S.D., Suman, K., Lakshmi, B.J., Manorama, R., Kumar, S., et al. Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels. Blood 122 (2013), 1478–1486.
29. [29] Ghoshal, S., T.R., Zhu, Q., Chakraborty, A., Inositol hexakisphosphate kinase-1 interacts with perilipin1 to modulate lipolysis. International Journal of Biochemistry & Cell Biology 78 (2016 Jun 29), 149–155.
30. [30] Chakraborty, A., L.C., Xu, J., Snyder, S.H., Beaulieu, J.M., Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways. Molecular Psychiatry 19 (2014), 284–293.
31. [31] Luo, H.R., S.A., Nagata, E., Ye, K., Yu, H., Jung, T.S., et al. GRAB: a physiologic guanine nucleotide exchange factor for Rab3A, which interacts with inositol hexakisphosphate kinase. Neuron 31 (2001), 439–451.
32. [32] Chakraborty, A., K.M., Bello, N.T., Maxwell, M., Potter, J.J., Juluri, K.R., et al. Inositol pyrophosphates inhibit Akt signaling, regulate insulin sensitivity and weight gain. Cell 143 (2010), 897–910.
33. [33] Illies, C., G.J., Fiume, R., Leibiger, B., Yu, J., Juhl, K., et al. Requirement of inositol pyrophosphates for full exocytotic capacity in pancreatic beta cells. Science 318 (2007), 1299–1302.
34. [34] Szijgyarto, Z., G.A., Azevedo, C., Saiardi, A., Influence of inositol pyrophosphates on cellular energy dynamics. Science 334 (2011), 802–805.
35. [35] Manning, B.D., C.L., AKT/PKB signaling: navigating downstream. Cell 129 (2007), 1261–1274.
36. [36] Summers, S.A., B.M., A role for the serine/threonine kinase, Akt, in insulin-stimulated glucose uptake. Biochemical Society Transactions 25 (1997), 981–988.
37. [37] Mackenzie, R.W., E.B., Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 13 (2014), 55–64.
38. [38] Cho, H., M.J., Kim, J.K., Thorvaldsen, J.L., Chu, Q., Crenshaw, E.B. 3rd, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292 (2001), 1728–1731.
39. [39] Izumiya, Y., H.T., Morris, C., Sato, K., Zeng, L., Viereck, J., et al. Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metabolism 7 (2008), 159–172.
40. [40] Hui, X., G.P., Zhang, J., Nie, T., Pan, Y., Wu, D., et al. Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promoting M2 macrophage proliferation. Cell Metabolism 22 (2015), 279–290.
41. [41] Karlsson, H.K., Z.J., Kane, S., Krook, A., Lienhard, G.E., Wallberg-Henriksson, H., Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 54 (2005), 1692–1697.
42. [42] Krook, A., R.R., Jiang, X.J., Zierath, J.R., Wallberg-Henriksson, H., Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 47 (1998), 1281–1286.
43. [43] Jordan, S.D., K.M., Willmes, D.M., Redemann, N., Wunderlich, F.T., Brönneke, H.S., et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nature Cell Biology 13 (2011), 434–446.
44. [44] Farese, R.V., S.M., Standaert, M.L., Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Experimental Biology and Medicine (Maywood) 230 (2005), 593–605.
45. [45] Prasad, A., J.Y., Chakraborty, A., Li, Y., Jain, S.K., Zhong, J., et al. Inositol hexakisphosphate kinase 1 regulates neutrophil function in innate immunity by inhibiting phosphatidylinositol-(3,4,5)-trisphosphate signaling. Nature Immunology 12 (2011), 752–760.
46. [46] Xu, Y., L.H., Bajrami, B., Kwak, H., Cao, S., Liu, P., et al. Cigarette smoke (CS) and nicotine delay neutrophil spontaneous death via suppressing production of diphosphoinositol pentakisphosphate. Proceedings of the National Academy of Sciences of the United States of America 110 (2013), 7726–7731.
47. [47] Luo, H.R., H.Y., Chen, J.C., Saiardi, A., Iijima, M., Ye, K., et al. Inositol pyrophosphates mediate chemotaxis in Dictyostelium via pleckstrin homology domain-PtdIns(3,4,5)P3 interactions. Cell 114 (2003), 559–572.
48. [48] Wu, M., D.B., Trevisan, A.J., Fiedler, D., Synthesis and characterization of non-hydrolysable diphosphoinositol polyphosphate second messengers. Chemical Science 4 (2013), 405–410.
49. [49] Pavlovic, I., T.D., Vargas, J.R., McKinlay, C.J., Hauke, S., Anstaett, P., et al. Cellular delivery and photochemical release of a caged inositol-pyrophosphate induces PH-domain translocation in cellulo. Nature Communications, 7, 2016, 10622.
50. [50] Rosen, E.D., S.B., What we talk about when we talk about fat. Cell 156 (2014), 20–44.
51. [51] Harms, M., S.P., Brown and beige fat: development, function and therapeutic potential. Nature Medicine 19 (2013), 1252–1263.
52. [52] N, T.G.a.M, Mantovani, G., (eds.) Diet-induced thermogenesis, 2006, Springer 4.
53. [53] Chang, Y.T., C.G., Bae, Y.S., Burdett, M., Moon, H.S., Lee, J.W., et al. Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. ChemBioChem 3 (2002), 897–901.
54. [54] Padmanabhan, U., D.D., Fridy, P.C., York, J.D., Downes, C.P., Characterization of a selective inhibitor of inositol hexakisphosphate kinases: use in defining biological roles and metabolic relationships of inositol pyrophosphates. Journal of Biological Chemistry 284 (2009), 10571–10582.
55. [55] Wang, H., F.J., Hall, T.M., Shears, S.B., Structural basis for an inositol pyrophosphate kinase surmounting phosphate crowding. Nature Chemical Biology 8 (2011), 111–116.
56. [56] Sun, D., L.S., Wu, H., Zhang, M., Zhang, X., Wei, L., et al. (OSM) protects against cardiac ischaemia/reperfusion injury in diabetic mice by regulating apoptosis, mitochondrial biogenesis and insulin sensitivity. Journal of Cellular and Molecular Medicine 19 (2015), 1296–1307.
57. [57] Zhang, Z., Z.C., Liu, B., Liang, D., Qin, X., Li, X., et al. Inositol pyrophosphates mediate the effects of aging on bone marrow mesenchymal stem cells by inhibiting Akt signaling. Journal of Stem Cell Research & Therapy, 5, 2014, 33.
58. [58] Sarmah, B., W.S., Inositol hexakisphosphate kinase-2 acts as an effector of the vertebrate Hedgehog pathway. Proceedings of the National Academy of Sciences of the United States of America 107 (2010), 19921–19926.
59. [59] Bhandari, R., J.K., Resnick, A.C., Snyder, S.H., Gene deletion of inositol hexakisphosphate kinase 1 reveals inositol pyrophosphate regulation of insulin secretion, growth, and spermiogenesis. Proceedings of the National Academy of Sciences of the United States of America 105 (2008), 2349–2353.
60. [60] Chakraborty, A., K.M., Sixt, K.M., Juluri, K.R., Mustafa, A.K., Snowman, A.M., et al. HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proceedings of the National Academy of Sciences of the United States of America 105 (2008), 1134–1139.
61. [61] Losito, O., S.Z., Resnick, A.C., Saiardi, A., Inositol pyrophosphates and their unique metabolic complexity: analysis by gel electrophoresis. PLoS One, 4, 2009, e5580.
62. [62] Tschöp, M.H., S.J., Arch, J.R., Auwerx, J., Brüning, J.C., Chan, L., et al. A guide to analysis of mouse energy metabolism. Nature Methods 9 (2011), 57–63.
63. [63] Baydyuk, M., X.Y., Tessarollo, L., Xu, B., Midbrain-derived neurotrophins support survival of immature striatal projection neurons. Journal of Neuroscience 33 (2013), 3363–3369.
64. [64] Regeur, L., P.B., Optimizing sampling designs for volume measurements of components of human brain using a stereological method. Journal of Microscopy 155 (1989), 113–121.
65. [65] Henninger, D.D., G.M., Granger, D.N., Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli. Circulation Research 81 (1997), 274–281.
66. [66] Sarbassov, D.D., G.D., Ali, S.M., Sabatini, D.M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005), 1098–1101.
67. [67] Alessi, D.R., J.S., Downes, C.P., Holmes, A.B., Gaffney, P.R., Reese, C.B., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Current Biology 7 (1997), 261–269.
68. [68] Rothwell, N.J., S.M., A role for brown adipose tissue in diet-induced thermogenesis. Obesity Research 5 (1997), 650–656.
69. [69] Kozak, L.P., A.-K.R, UCP1: its involvement and utility in obesity. International Journal of Obesity (Lond) 32:Suppl. 7 (2008), S32–S38.
70. [70] Chechi, K., N.J., Richard, D., Brown adipose tissue as an anti-obesity tissue in humans. Obesity Review, 2013.
71. [71] Bachman, E.S., D.H., Zhang, C.Y., Cinti, S., Bianco, A.C., Kobilka, B.K., et al. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 297 (2002), 843–845.
72. [72] Gimeno, R.E., M.D., FGF21-based pharmacotherapy–potential utility for metabolic disorders. Trends in Endocrinology and Metabolism 25 (2014), 303–311.
73. [73] Cypess, A.M., W.L., Roberts-Toler, C., Franquet Elía, E., Kessler, S.H., Kahn, P.A., et al. Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. Cell Metabolism 21 (2015), 33–38.
74. [74] Collins, S., A heart-adipose tissue connection in the regulation of energy metabolism. Nature Reviews Endocrinology 10 (2014), 157–163.
75. [75] Smith, D.A., D.L., Kerns, E.H., The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nature Reviews Drug Discovery 9 (2010), 929–939.
76. [76] Bi, P., S.T., Liu, W., Yue, F., Yang, X., Liang, X.R., et al. Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity. Nature Medicine, 2014.
77. [77] Boström, P., W.J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481 (2012), 463–468.
78. [78] Pilch, P.F., B.N., Pharmacological targeting of adipocytes/fat metabolism for treatment of obesity and diabetes. Molecular Pharmacology 70 (2006), 779–785.
79. [79] Cypess, A.M., K.C., Brown fat as a therapy for obesity and diabetes. Current Opinion in Endocrinology Diabetes and Obesity 17 (2010), 143–149.
80. [80] Cypess, A.M., L.S., Williams, G., Tal, I., Rodman, D., Goldfine, A.B., et al. Identification and importance of brown adipose tissue in adult humans. New England Journal of Medicine 360 (2009), 1509–1517.
81. [81] Müller, M.J., B.-W.A., Adaptive thermogenesis with weight loss in humans. Obesity (Silver Spring) 21 (2013), 218–228.
82. [82] Yoneshiro, T., A.S., Matsushita, M., Kayahara, T., Kameya, T., Kawai, Y., et al. Recruited brown adipose tissue as an antiobesity agent in humans. Journal of Clinical Investigation 123 (2013), 3404–3408.
83. [83] Rao, F., X.J., Fu, C., Cha, J.Y., Gadalla, M.M., Xu, R., et al. Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1. Proceedings of the National Academy of Sciences of the United States of America, 2015.
84. [84] Rao, F., C.J., Xu, J., Xu, R., Vandiver, M.S., Tyagi, R., et al. Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2. Molecular Cell 54 (2014), 119–132.
85. [85] Hinoi, E., I.T., Fujita, H., Watanabe, T., Odaka, Y., Ozaki, K., et al. PI3K/Akt is involved in brown adipogenesis mediated by growth differentiation factor-5 in association with activation of the Smad pathway. Biochemical and Biophysical Research 450 (2014), 255–260.
86. [86] Valverde, A.M., A.M., Mur, C., Navarro, P., Pons, S., Cassard-Doulcier, A.M., et al. Insulin-induced up-regulated uncoupling protein-1 expression is mediated by insulin receptor substrate 1 through the phosphatidylinositol 3-kinase/Akt signaling pathway in fetal brown adipocytes. Journal of Biological Chemistry 278 (2003), 10221–10231.
87. [87] Zhang, H., G.M., Townsend, K.L., Huang, T.L., An, D., Yan, X., et al. MicroRNA-455 regulates brown adipogenesis via a novel HIF1an-AMPK-PGC1α signaling network. EMBO Reports 16 (2015), 1378–1393.
88. [88] van Dam, A.D., K.S., Schilperoort, M., Rensen, P.C., Boon, M.R., Regulation of brown fat by AMP-activated protein kinase. Trends in Molecular Medicine, 2015 S1471–4914(15)00136-7.
89. [89] Shinoda, K., O.K., Hasegawa, Y., Chang, H.Y., Ogura, M., Sato, A., et al. Phosphoproteomics identifies CK2 as a negative regulator of beige adipocyte thermogenesis and energy expenditure. Cell Metabolism 22 (2015), 997–1008.
90. [90] Cantó, C., A.J., PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Current Opinion in Lipidology 20 (2009), 98–105.
91. [91] Cheng, C.Y., M.D., The blood-testis barrier and its implications for male contraception. Pharmacological Reviews 64 (2012), 16–64.
92. [92] Fu, C., X.J., Li, R.J., Crawford, J.A., Khan, A.B., Ma, T.M., et al. Inositol hexakisphosphate Kinase-3 regulates the morphology and synapse formation of cerebellar purkinje cells via spectrin/adducin. Journal of Neuroscience 35 (2015), 11056–11067.
93. [93] Stork, C.J., L.Y., Zinc release from thapsigargin/IP3-sensitive stores in cultured cortical neurons. Journal of Molecular Signaling, 5, 2010, 5.
94. [94] Eva, R., B.-C.D., Patel, K., Cullen, P.J., Banting, G., IP3 3-kinase opposes NGF driven neurite outgrowth. PLoS One, 7, 2012, e32386.
95. [95] Sekar, M.C., S.K., Leloup, L., Wells, A., Modulation of epidermal growth factor stimulated ERK phosphorylation and cell motility by inositol trisphosphate kinase. Journal of Pharmaceutical Sciences and Pharmacology 1 (2014), 160–164.
96. [96] Kamimura, J., W.K., Kadowaki, H., Watanabe, Y., Miyake, K., Harada, N., et al. The IHPK1 gene is disrupted at the 3p21.31 breakpoint of t(3;9) in a family with type 2 diabetes mellitus. Journal of Human Genetics 49 (2004), 360–365.